IDEAYA Biosciences Announces First-Patient-in for Phase 1 Clinical Trial Evaluating Ide397 and Trodelvy® Combination in Mtap-Deletion Bladder Cancer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.